Rivaroxaban for cancer-associated venous thromboembolism: A systematic review and meta-analysis protocol

BACKGROUND: All cancers increase developing venous thromboembolism risk, and VTE is the second-leading cause of death among cancer patients. The anticoagulant drugs are considered to be the optimal treatment for patients with cancer-associated VTE. However, there is still controversy whether rivarox...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Bo, Zhao, Li-Zhi, Liao, Hui-Ling, Gu, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890290/
https://www.ncbi.nlm.nih.gov/pubmed/31770226
http://dx.doi.org/10.1097/MD.0000000000018087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890290/
https://www.ncbi.nlm.nih.gov/pubmed/31770226
http://dx.doi.org/10.1097/MD.0000000000018087

Ejemplares similares